Share Issue/Capital Change • Dec 28, 2018
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Lund, Sweden, 18:00 CET 28 December 2018 - During December, the number of shares and votes in BONESUPPORT HOLDING AB(publ) has increased due to the exercise of warrants. Asof 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB(publ) amounts to 51,795,917.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
Pip Batty, David Dible, Shabnam Bashir
+44 (0)20 7282 1022
BONESUPPORT(Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit www.bonesupport.com for more information.
The information in the press release is such that BONESUPPORTHOLDINGAB (publ) is required to disclose pursuant to the Swedish Financial Instruments TradingAct. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CETon 28 December 2018.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.